AzTrials
AzTrials

Type 1 DiabetesNCT07097818

Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2

A study testing T1D team, structured education, peer support , and diabetes technologies and Routine Management in people with Type 1 Diabetes, run by Second Xiangya Hospital of Central South University at 10 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes. Read more about this study

Who is it for?
Ages 6 years and older
Conditions the study is for
Type 1 Diabetes
What is being tested?
T1D team, structured education, peer support , and diabetes technologies and Routine Management
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
10 sitesChina
Study dates
18 Aug 2025to 1 Apr 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • Patients who plan to receive diabetes treatment at other hospitals.
  • Patients who have used an automated insulin delivery system or sensor-augmented pump within 3 months prior to screening.
  • Patients who refuse to use continuous glucose monitoring or insulin pumps, or refuse data upload and remote monitoring.
  • Patients with severe cardiovascular, cerebrovascular, hepatic, or renal diseases; uncontrolled systemic diseases, thyroid diseases; autoimmune diseases; or malignancies.
  • Patients diagnosed with hematologic or bleeding disorders.
  • Patients who have received red blood cell transfusions or erythropoiesis-stimulating agents within 3 months prior to screening.
Show all 15Show fewer
  • Patients who have used any oral, injectable, or intravenous corticosteroids within 8 weeks prior to screening, or who plan to use corticosteroids during the trial.
  • Patients with severe skin diseases that may affect the application sites of continuous glucose monitoring or insulin pump patches.
  • Patients with auditory or visual impairments.
  • Patients with alcohol or drug abuse.
  • Patients who plan to receive blood transfusions during the study period.
  • Patients who plan to undergo elective surgery requiring general anesthesia or dialysis during the study period.
  • Pregnant women, women planning to become pregnant within 1 year of the study, or women who are breastfeeding.
  • Patients who are currently participating in or have participated in other drug or device trials within the last 2 weeks.
  • Patients who, in the investigator's opinion, are not suitable for participation in this clinical trial, such as those with a history of vision impairment, eating disorders, celiac disease, etc.

Trial locations and contacts

10 sites in 1 country. Contact the study team or a site near you to ask about taking part.

10 sites in 1 country

China10 sites, 10 recruiting
  • Department of Endocrinology and Metabolism, Peking University People's Hospital

    Beijing, Beijing Municipality

    Xiaoling Cai, dr_junel@sina.com

    Not yet recruiting
  • Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University

    Changsha, Hunan, 410011

    Xia Li, MD, PhD, +86 13974885753, lixia2014@vip.163.com

    Recruiting
  • Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan University

    Chengdu, Sichuan

    Nanwei Tong, tongnw@scu.edu.cn

    Not yet recruiting
  • Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health

    Hangzhou, Zhejiang

    Junfen Fu, fjf68@zju.edu.cn

    Not yet recruiting
  • Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology

    Luoyang, Henan, 471003

    Hongwei Jiang, jianghw@haust.edu.cn

    Recruiting
  • Department of Endocrinology, Quanzhou First Hospital Affiliated to Fujian Medical University

    Quanzhou, Fujian

    Yi Zhang, zhangyi135@qzdyyy.com

    Not yet recruiting
  • Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning

    Yanli Cao, vanilla421@163.com

    Not yet recruiting
  • Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University

    Shenzhen, Guangdong

    Haiyan Li, haiyanli78@163.com

    Not yet recruiting
  • Second Department of Endocrinology and Metabolism, Tangshan Gongren Hospital

    Tangshan, Hebei

    Hui Fang, fanghui2818@126.com

    Not yet recruiting
  • Department of Endocrinology, Zhongnan Hospital of Wuhan University

    Wuhan, Hubei

    Zhe Dai, daizhe@znhospital.cn

    Not yet recruiting

Other trials in China

About this study

Official title: Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2: a Multicentre, Cluster-randomized, Controlled Trial

The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes.

Read the detailed description

Type 1 diabetes (T1D) is a lifelong metabolic disease with an increasing disease burden. Despite continuous advancements in diagnostic and treatment technologies, patients of all age groups fail to meet the glycemic targets. Currently, there is a common deficiency in the management of T1D both domestically and internationally, which is specifically manifested as: the disconnection between blood glucose monitoring and insulin adjustment, low utilization rate of new technologies, insufficient patient self-management training, and the absence of psychological intervention, etc.

This GLITTER Study 2 extends the GLITTER Study (Glycemic Improvement with Team, Technology, Education and Peer Resources in type 1 diabetes) by implementing its philosophy (Team, Technology, Education, Peer Resources) to develop a comprehensive T1D management model, integrating these components to enhance management and evaluate effectiveness.

This multicentre, cluster-randomized controlled trial will be conducted across 10 hospitals. It aims to enroll patients with T1D aged ≥6 years who have had the disease for >3 months. Five hospitals were randomly assigned to the comprehensive management intervention group, and five to the usual care group. A total of 400 individuals were recruited into the study. The intervention for the intervention group includes: T1D team (dedicated T1D physicians, certified diabetes educators, registered dietitians), centralized structured education (courses, short videos, and structured educational materials), peer support (volunteer matching, camp, volunteer peer live streaming), and diabetes technologies (insulin pumps and continuous glucose monitoring). The control group received usual care, with the five assigned hospitals continuing their clinical practice. This 52-week trial includes assessments at the following timepoints: screening, week 13 (visit 2), week 26 (visit 3), week 39 (visit 4), and week 52 (visit 5). Throughout the study period, we will evaluate the model's impact on glycemic control and psychosocial outcomes, aiming to establish an evidence-based clinical practice paradigm for T1D management.

Conditions
Type 1 Diabetes
Being tested
T1D team, structured education, peer support , and diabetes technologies, Routine Management
Keywords
Type 1 diabetes, Comprehensive management, T1D teams, Structured education, Peer resources, Diabetes technologies, Glycemic control
Medical subject headings
Diabetes Mellitus, Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • T1D team, structured education, peer support , and diabetes technologiesBehavioural

    Patients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities.

  • Routine ManagementBehavioural

    Patients with T1D will be managed according to the routine diagnosis and education model of each hospital.

Study groups in NCT07097818
Study groupRoleWhat they receive
Intervention groupExperimentalPatients with T1D in the intervention group will undergo comprehensive management.
Receives: Behavioral: T1D team, structured education, peer support , and diabetes technologies
Control groupOtherPatients with T1D in the control group will receive routine management.
Receives: Behavioral: Routine Management

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in HbA1c

    The primary outcome is the Change in Glycated Hemoglobin A1C (HbA1c) before and after the 52 weeks intervention. HbA1c is a physiological marker of the percentage of red blood cells that have glycated (bonded with a sugar). HbA1c is used to measure changes in average blood sugar over the past three months.

    Measured: Baseline, 13, 26, and 52 weeks

Secondary outcomes (23)
  1. Percentage of patients in each group with HbA1c <7.0%

    HbA1c serves as a crucial physiological marker for assessing average blood sugar levels over the preceding three months. Values below 7.0 are deemed optimal for long-term health. Consequently, a higher number or percentage of individuals achieving an HbA1c level below 7.0 is indicative of a positive outcome, reflecting better glycemic control and reduced risk of complications.

    Measured: 52 weeks

  2. Percentage of patients in each group with HbA1c <7.5%

    HbA1c serves as a crucial physiological marker for assessing average blood sugar levels over the preceding three months. Values below 7.5 are deemed optimal for long-term health. Consequently, a higher number or percentage of individuals achieving an HbA1c level below 7.5 is indicative of a positive outcome, reflecting better glycemic control and reduced risk of complications.

    Measured: 52 weeks

  3. CGM-measured Percentage Time 70-180 mg/dL (3.9-10.0 mmol/L)

    The CGM-measured percentage time 70-180 mg/dL (3.9-10.0 mmol/L) refers to the proportion of time during which an individual's blood glucose levels, as continuously monitored by a CGM device. This metric is crucial for assessing glycemic control in individuals with diabetes. Maintaining blood glucose within this target range is associated with better health outcomes and reduced risk of complications.

    Measured: Baseline, 13, 26, and 52 weeks

  4. CGM-measured Percentage Time >180 mg/dL (>10.0 mmol/L)

    Smaller percentages of CGM-measured time above 180 mg/dL is considered a positive outcome.

    Measured: Baseline, 13, 26, and 52 weeks

  5. CGM-measured Percentage Time >250 mg/dL (>13.9 mmol/L)

    CGM measured blood sugar values above 250 mg/dL are considered to be undesirable. Thus, less time spent above 250mg/dL is considered a positive outcome.

    Measured: Baseline, 13, 26, and 52 weeks

  6. CGM-Measured Percentage Time <70 mg/dL (<3.9 mmol/L)

    Blood sugar values measured by CGM that fall below 70 mg/dL are considered potentially hazardous, as they may lead to unconsciousness and, in severe cases, even death. Therefore, minimizing the time spent below 70 mg/dL is regarded as a highly positive outcome, reflecting better management of low blood sugar episodes and enhanced safety for the individual.

    Measured: Baseline, 13, 26, and 52 weeks

  7. CGM-Measured Percentage Time <60 mg/dL (<3.3 mmol/L)

    Blood sugar values measured by CGM that fall below 60 mg/dL are considered potentially hazardous, as they may lead to unconsciousness and, in severe cases, even death. Therefore, minimizing the time spent below 60 mg/dL is regarded as a highly positive outcome, reflecting better management of low blood sugar episodes and enhanced safety for the individual.

    Measured: Baseline, 13, 26, and 52 weeks

  8. CGM-measured Glucose Standard Deviation (SD)

    Standard Deviation represents how much glucose levels fluctuate over time from a given average.

    Measured: Baseline, 13, 26, and 52 weeks

  9. CGM-Measured Glucose Coefficient of Variation

    The Coefficient of Variability (CV) is calculated as the ratio of the standard deviation to the mean of blood sugar values for each participant, as measured by CGM. The reported CV value is derived by multiplying the ratio of the standard deviation to the mean by 100, providing a percentage that reflects the degree of variability in blood sugar levels across the population. A higher CV value, which can range up to 100, signifies greater dispersion of CGM values, indicating more significant fluctuations in blood sugar levels. This increased variability is generally considered an unfavorable outcome, as it may suggest less stable glucose control. Conversely, the minimum CV value is 0, which would indicate no variability in blood sugar levels, representing perfect stability.

    Measured: Baseline, 13, 26, and 52 weeks

  10. CGM-Measured Glucose Risk Index (GRI)

    The CGM-Measured Glucose Risk Index (GRI) is a comprehensive metric derived from CGM data, designed to quantify the overall risk associated with blood glucose variability. It integrates multiple aspects of glucose levels, including the frequency and severity of both hypo- and hyperglycemic events, as well as the duration of time spent outside the target glucose range. A lower GRI score indicates better glucose stability and lower risk of adverse outcomes related to blood sugar fluctuations.

    Measured: Baseline, 13, 26, and 52 weeks

  11. Self-Management of Type 1 Diabetes for Chinese Adults

    The Self-Management of Type 1 Diabetes for Chinese Adults (SMOD-CA) scale is a validated instrument specifically designed to assess the self-management behaviors and capabilities of adults with type 1 diabetes in the Chinese population. The SMOD-CA consists of 30 items. Responses are rated on a five-point scale, with higher scores indicating better self-management ability. The total score ranges from 0 to 120.

    Measured: Baseline and 52 weeks

  12. 23-item Chinese Version of Self-Report Measure of Self-Management of Type 1 Diabetes for Adolescents

    The 23-item Chinese Version of Self-Report Measure of Self-Management of Type 1 Diabetes for Adolescents (C-SMOD-A-23) is a validated and simplified instrument designed to assess the self-management behaviors and capabilities of adolescents with type 1 diabetes.

    Measured: Baseline and 52 weeks

  13. Assessment of sleep quality: Pittsburgh Sleep Quality Index

    Pittsburgh Sleep Quality Index (PSQI), a self-report questionnaire comprising seven component scores (subjective sleep quality, sleep latency, duration of sleep, sleep efficiency habits, sleep disturbances, use of sleeping medication, and daytime dysfunction), is used to evaluate sleep quality over the last month.

    Measured: Baseline and 52 weeks

  14. Hypoglycemic Fear Scale

    The Hypoglycemic Fear Scale is a widely used and validated assessment tool designed to measure the level of fear and anxiety that individuals with diabetes, particularly those with type 1 diabetes, experience in relation to hypoglycemia (low blood sugar).

    Measured: Baseline and 52 weeks

  15. Diabetes Technology Attitude Scale

    The Diabetes Technology Attitude Scale is a specialized assessment tool designed to evaluate individuals' attitudes toward diabetes-related technologies.

    Tool lists statement and participants reports how much they agree with the statement.

    Measured: Baseline and 52 weeks

  16. Barriers to Technology

    The Barriers to Technology Questionnaire typically consists of several key sections, each designed to capture different aspects of technology adoption and use.

    Measured: Baseline and 52 weeks

  17. Diabetes Treatment Satisfaction Questionnaire

    The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a comprehensive and widely utilized tool designed to assess the level of satisfaction that individuals with diabetes have with their current treatment regimens. The DTSQ is usually administered as a self-report questionnaire, allowing patients to rate their responses on a Likert scale, typically ranging from "very dissatisfied" to "very satisfied." The total score is calculated by summing the responses to all relevant items, with higher scores indicating greater satisfaction with the treatment.

    Measured: Baseline and 52 weeks

  18. Diagnosis and measurement of the severity of depression: Patient Health Questionnaire

    The Patient Health Questionnaire (PHQ-9) will be used to assess depressive symptoms, including suicidal ideation, over the last two weeks (9 questions). Items are scored 0-3, resulting in a total score of 0-27. Higher scores indicate more symptoms of depression.

    Measured: Baseline and 52 weeks

  19. Depression Self-Rating Scale for Children

    The Depression Self-Rating Scale for Children (DSRSC) is a standardized psychological assessment tool designed to measure depressive symptoms in children and adolescents. This self-report inventory allows young individuals to rate the frequency and severity of various depressive feelings and behaviors they may be experiencing.

    Measured: Baseline and 52 weeks

  20. Generalized Anxiety Disorder 7-item scale

    The Generalized Anxiety Disorder 7-item scale (GAD-7) consists of seven items. Each item asks respondents to rate how often they have been bothered by specific anxiety-related symptoms over the past two weeks.

    Measured: Baseline and 52 weeks

  21. WHO-5 Well-Being Index

    The WHO-5 Well-Being Index (WHO-5) is a brief, self-report questionnaire designed to assess subjective well-being. The WHO-5 consists of five simple and straightforward items. Each item is rated on a 6-point Likert scale, ranging from 0 (not present) to 5 (constantly present). The total score is calculated by summing the responses to all five items, resulting in a score that ranges from 0 to 25. Higher scores indicate better well-being.

    Measured: Baseline and 52 weeks

  22. Evaluation of the perception of hypoglycemia in the population tested with Clarke score

    Clarke Hypoglycemia Awareness Scores (0-7 score with higher scores associated with impaired awareness).

    Measured: Baseline and 52 weeks

  23. Evaluation of the perception of hypoglycemia in the population tested with Gold score

    The Gold method is used to assess impaired awareness of hypoglycemia. The scale is from 1 to 7. A score of 4 or more indicates impaired awareness of hypoglycemia.

    Measured: Baseline and 52 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2025
  2. Study start18 Aug 2025
  3. Primary completion1 Mar 2027 (estimated)
  4. Study completion1 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07097818
Sponsor's protocol ID
KYZ20250019
Status last verified
Jul 2025
First submitted
24 Jul 2025
Last updated
3 Sep 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing T1D team, structured education, peer support , and diabetes technologies and Routine Management in people with Type 1 Diabetes, run by Second Xiangya Hospital of Central South University at 10 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Xia Li (+86 13974885753, lixia2014@vip.163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in HbA1c (time frame: Baseline, 13, 26, and 52 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in